![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
Zerviate (cetirizine hydrochloride) is an antihistamine, is a histamine-1 (H1) receptor antagonist. Its effects are mediated via selective inhibition of H1 histamine receptors, it is indicated for treatment of ocular itching associated with allergic conjunctivitis.
Lead Product(s): Cetirizine Dihydrochloride
Therapeutic Area: Ophthalmology Product Name: Zerviate
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: OcuMension Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2023
Details:
Zerviate (cetirizine hydrochloride) is a histamine-1 (H1) receptor antagonist. Its effects are mediated via selective inhibition of H1 histamine receptors. It is approved in China for ocular itching associated with allergic conjunctivitis.
Lead Product(s): Cetirizine Dihydrochloride
Therapeutic Area: Dermatology Product Name: Zerviate
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: Nicox SA
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2023
Details:
First randomized, double-blind, controlled trial evaluating IV cetirizine versus IV diphenhydramine in the prevention of hypersensitivity infusion reactions. QUZYTTIR is the first and only injectable second-generation H1 antihistamine to be approved by the U.S. FDA.
Lead Product(s): Cetirizine Dihydrochloride
Therapeutic Area: Oncology Product Name: Quzyttir
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2021
Details:
SGC scientists have developed a suite of technologies that enable the incorporation of various drug compounds into a novel gummy matrix, thus solving drug solubility, stability, and taste issues.
Lead Product(s): Cetirizine Dihydrochloride
Therapeutic Area: Immunology Product Name: Ceteric Allergy Gummy
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020